Medical economics
New RSV vaccine for older adults can result in individual and societal cost savings, benefits
Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.
Sep 5, 2024
0
0